A carregar...
Publicação
Peginterferon alfa-2a (40KD) plus 800 or 1000/1200 mg/day ribavirin in genotype 1 HIV–HCV co-infected patients: early responses to treatment and predictability for SVR in the PARADIGM study
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 72.34 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Descrição
Palavras-chave
Peginterferão alfa-2a Peginterferon alfa-2a Ribavirina Ribavirin Infecção por HIV HIV infections Hepatite C Hepatitis C PARADIGM study
Contexto Educativo
Citação
In: INTERNATIONAL LIVER CONGRESS. Annual Meeting of the European Association for the Study of the Liver, 45, Vienna, 14-18 April, 2010
Editora
European Association for the Study of the Liver